Literature DB >> 22387152

Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors.

Alfredo Corallini1, Elisa Mazzoni, Angelo Taronna, Marco Manfrini, Giovanni Carandina, Giovanni Guerra, Roberto Guaschino, Francesca Vaniglia, Corrado Magnani, Ferruccio Casali, Riccardo Dolcetti, Caterina Palmonari, Giovanni Rezza, Fernanda Martini, Giuseppe Barbanti-Brodano, Mauro G Tognon.   

Abstract

Simian virus 40 (SV40), a small DNA tumor virus, was inadvertently administered to human populations with the use of contaminated vaccines. SV40 sequences have mainly been detected in healthy individuals and cancer patients using polymerase chain reaction techniques. However, some studies have failed to reveal the presence of SV40 in human specimens. These conflicting results indicate the need for new research to verify whether SV40 is circulating in humans. Mimotopes from SV40 structural peptides were tested to investigate for specific reactions to human sera antibodies. An indirect enzyme-linked immunosorbent assay with synthetic peptides from SV40 viral capsid proteins 1-2-3 (VPs 1-2-3) was set up and employed to test 855 serum samples from healthy blood donors. Data from immunologic assays indicate that serum antibodies against SV40 VP mimotopes are detectable, although with a low titer, in blood donors 18 to 65 years old. The overall prevalence of serum samples that reacted with the 2 SV40 VP peptides was 18%. The strong points for this novel method include the simplicity of its approach and the potential to discriminate between SV40-specific antibody responses and to draw correlations between responses to the 2 independent SV40 peptides. These data suggest that SV40, or a yet undetected closely related polyomavirus, is circulating in human populations, but with lower prevalence than that of the ubiquitous BK and JC human polyomaviruses.
Copyright © 2012 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387152     DOI: 10.1016/j.humimm.2012.02.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  24 in total

Review 1.  Patterns of polyomavirus SV40 infections and associated cancers in humans: a model.

Authors:  Janet S Butel
Journal:  Curr Opin Virol       Date:  2012-07-06       Impact factor: 7.090

2.  SV40 seroprevalence in two Latin American countries involved in field trials of candidate oral poliovaccines.

Authors:  Connie Wong; Shaojie Zhang; Ervin Adam; Lawrence Paszat; Janet S Butel
Journal:  J Infect       Date:  2019-04-06       Impact factor: 6.072

3.  High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma.

Authors:  Elisa Mazzoni; Alfredo Corallini; Alfonso Cristaudo; Angelo Taronna; Gianfranco Tassi; Marco Manfrini; Manola Comar; Massimo Bovenzi; Roberto Guaschino; Francesca Vaniglia; Corrado Magnani; Ferruccio Casali; Giovanni Rezza; Giuseppe Barbanti-Brodano; Fernanda Martini; Mauro G Tognon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-15       Impact factor: 11.205

4.  Antibodies reacting with Simian virus 40 mimotopes in serum samples from patients with thalassaemia major.

Authors:  Caterina Borgna-Pignatti; Elisa Mazzoni; Marcella Felletti; Giuliana Turlà; Cristina Malaventura; Maria Domenica Cappellini; Paolo Cianciulli; Gian Luca Forni; Alfredo Corallini; Fernanda Martini; Mauro Tognon
Journal:  Blood Transfus       Date:  2014-03-19       Impact factor: 3.443

5.  Ethnic differences in polyomavirus simian virus 40 seroprevalence among women in Houston, Texas.

Authors:  Connie Wong; Regis A Vilchez; Jorge Quiroz; Ervin Adam; Janet S Butel
Journal:  J Infect       Date:  2012-08-30       Impact factor: 6.072

6.  Significant prevalence of antibodies reacting with simian virus 40 mimotopes in sera from patients affected by glioblastoma multiforme.

Authors:  Elisa Mazzoni; Massimo Gerosa; Francesco Lupidi; Alfredo Corallini; Angelo Pio Taronna; Antonio D'Agostino; Massimo Bovenzi; Giuseppina Ruggeri; Ferruccio Casali; John Charles Rotondo; Giovanni Rezza; Giuseppe Barbanti-Brodano; Mauro Tognon; Fernanda Martini
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

7.  Crystallographic and glycan microarray analysis of human polyomavirus 9 VP1 identifies N-glycolyl neuraminic acid as a receptor candidate.

Authors:  Zaigham Mahmood Khan; Yan Liu; Ursula Neu; Michel Gilbert; Bernhard Ehlers; Ten Feizi; Thilo Stehle
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

8.  Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus.

Authors:  Elena Torreggiani; Ilaria Bononi; Silvia Pietrobon; Elisa Mazzoni; Giovanni Guerra; Carlo Feo; Fernanda Martini; Mauro Tognon
Journal:  Front Immunol       Date:  2021-05-25       Impact factor: 7.561

9.  An antibody response to human polyomavirus 15-mer peptides is highly abundant in healthy human subjects.

Authors:  Lieven J Stuyver; Tobias Verbeke; Tom Van Loy; Ellen Van Gulck; Luc Tritsmans
Journal:  Virol J       Date:  2013-06-12       Impact factor: 4.099

10.  Serological evidence of an early seroconversion to Simian virus 40 in healthy children and adolescents.

Authors:  Angelo Taronna; Elisa Mazzoni; Alfredo Corallini; Ilaria Bononi; Silvia Pietrobon; Giovanni Guerra; Caterina Palmonari; Caterina Borgna-Pignatti; Manola Comar; Massimo Bovenzi; Ferruccio Casali; Roberto Marci; Giovanni Rezza; Giuseppe Barbanti-Brodano; Mauro Tognon; Fernanda Martini
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.